{"id":"W2692549261","doi":"10.1200/jco.2017.35.15_suppl.e12534","title":"Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Pfizer (Canada); Hôpital du Saint-Sacrement; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Internal medicine; Adverse effect; Hazard ratio; Gastroenterology; Palbociclib; Expanded access; Surgery; Toxicity; Cancer; Breast cancer; Metastatic breast cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009839789,0.0004412454,0.0005801877,0.0002831295,0.0006060627,0.0005573109,0.0006719999,0.000660829,0.003245194],"category_scores_gemma":[0.001685771,0.0002245527,0.0005517737,0.0005270804,0.000646065,0.0003256624,0.0003142009,0.001188328,0.0003352805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007713445,"about_ca_system_score_gemma":0.01048373,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.2446881,"about_ca_topic_score_gemma":0.4413671,"domain_scores_codex":[0.999509,0.0001205822,0.00001498408,0.0000755121,0.0001984614,0.00008140849],"domain_scores_gemma":[0.9991283,0.0001033707,0.0002240261,0.00004843536,0.000175509,0.0003203347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5961789,0.01229968,0.07163218,0.001226607,0.001983365,0.0003222128,0.0006152029,0.002068809,0.01533151,0.0003954888,0.01804179,0.2799042],"study_design_scores_gemma":[0.1772743,0.2723263,0.5061583,0.0003119973,0.004000777,0.0009906595,0.0004041627,0.00347307,0.006958303,0.0003104434,0.02768097,0.0001107458],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866645,0.002002962,0.0002369719,0.0006006438,0.00003016506,0.0009127856,0.004625093,0.00006595381,0.004860927],"genre_scores_gemma":[0.9929328,0.001036496,0.0003583818,0.0004351771,0.00004740042,0.0002925879,0.003058207,0.00001176804,0.001827365],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7553118,"threshold_uncertainty_score":0.4865278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0559032773756887,"score_gpt":0.4206166147625556,"score_spread":0.364713337386867,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}